Pieris Pharmaceuticals Inc
PIRS
Market Cap$17.96M
Close$
Share Statistics
| Market cap | $17.96 Million |
|---|---|
| Enterprise Value | $-53,229,736.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-7.83 |
| Beta | 0.66 |
| Outstanding Shares | 11,013,697 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.23 |
|---|---|
| PEG | -10.74 |
| Price to Sales | -13.6 |
| Price to Book Ratio | 2.72 |
| Enterprise Value to Revenue | 1004.33 |
| Enterprise Value to EBIT | 3.1 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | -0.08 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Palvella Therapeutics, Inc.
14 employees
CEO: Mr. Wesley H. Kaupinen Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamy...